Article
An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).
All News
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Article
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
Article
Concerns about the long-term safety of hydroxychloroquine (HCQ) often results in dose reduction or drug discontinuation; yet a current study shows that, for those in remission, HCQ taper/discontinuation resulted in a significantly higher rate of SLE flares.
Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.
Article
The American College of Rheumatology (ACR) is launching two new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Educatio
Article
Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.
Dr. John Cush
Tweet
RheumNow Live is Coming to Town!
Have you signed up for RheumNow Live yet? We still have space available.
https://t.co/FBCQRu32gO
https://t.co/KoGR8An6af https://t.co/qtwPbMzqSO
Dr. John Cush
Tweet
Could Anifrolumab Work in Lupus Nephritis?
Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.
https://t.co/6EtLf1nhv6 https://t.co/RrJX08vcIK
Dr. John Cush
Tweet
New Download Available!
Autoimmune Disease in the USA
https://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6
Dr. John Cush
Tweet
ICYMI: Increased SLE Flares with HCQ Reduction
Concerns about the long-term safety of HCQ often results in dose reduction or drug discontinuation; study shows that, for those in remission, HCQ taper/discontinuation resulted in a higher rate of SLE flares.
https://t.co/l0Xh1oQzQA https://t.co/HyDbqKrEFp
Dr. John Cush
Tweet
2/28, was “Rare Disease Day” in the USA, w/many tributes to the patients, doctors & researchers dedicated to these disorders. Moreover, it was a great opportunity to shout about the many rare conditions that don’t get enough press, praise or funding.
https://t.co/ft8Y8Mmdnz https://t.co/WqhRGzNRtS
Dr. John Cush
Tweet
Listen in… Fellow Case Presentations From RWCS 2022
https://t.co/SvaGfyDDTK https://t.co/MP9iWQK8ZB
Dr. John Cush
Tweet
ICYMI: 144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/YqxPFtYohf
Dr. John Cush
Tweet
SLE mortality rates (ASMR) nearly doubled since 1998 & remain high (vs non-SLE mortality) w/ significant sex & regional disparities. Data from 11449 SLE deaths, ASMR signif increased 1998 to 2009, down 2009 to 2013 and increased thereafter https://t.co/kSc3Cn2Bl5
Dr. John Cush
Tweet
144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/Js5jB6hlox
Dr. John Cush
Tweet
CSF aptamer (short nucleic acid sequences) discovery of neuropsychiatric lupus pts finds increase in few CSF proteins that are discriminatory -- CSF Lipocalin-2, M-CSF, IgM and complement C3, the latter assoc w/ acute confusional state. https://t.co/Mvp2U8DMh8
Dr. John Cush
Tweet
ICYMI: Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/29HupHHOW6
Dr. John Cush
Tweet
ICYMI: Challenges in Lupus:
-Mortality greatest in 1st yr
-Dx Delays 6.4 yrs
-Long-term complications increased 50 fold
-Steroids worsen long-term outcomes
-Health care costs increased 3 to 5 years prior to Dx
-Mean delay in drug starts after Dx =177 days https://t.co/ZMHTXBn4vm https://t.co/SX0fSxHoES
Dr. John Cush
Tweet
Predicting Treatment Response in Inflammatory Muscle Disorders
Rheums looking for clues to whether their patients w/certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study in Arthritis Care & Research.
https://t.co/kXFIEMTbkb https://t.co/UbO7nSsdAY
